+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Cachexia Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797977
The global cancer cachexia market size attained a value of USD 2.22 billion in 2022. The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2023-2031 to attain a value of USD 3.36 billion by 2031.

Cancer Cachexia Market: Introduction

Cancer cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle mass with or without loss of fat mass. It is a common complication in cancer patients, particularly those with advanced disease, and can significantly affect quality of life and survival outcomes.

Cachexia is more than just weight loss. It is a multifactorial condition that includes symptoms such as anorexia (loss of appetite), inflammation, insulin resistance, and increased muscle protein breakdown. Despite nutritional interventions, weight loss often continues in patients with cancer cachexia because the body's metabolism and protein synthesis processes are negatively impacted.

The exact mechanisms causing cachexia in cancer patients are complex and not fully understood, but it is known to involve several factors:
1. Tumour-induced factors: The tumour itself can release certain substances (known as pro-inflammatory cytokines) which can lead to muscle and fat tissue wasting. Some of these substances include tumour necrosis factor-alpha (TNF-a), interleukin-1 (IL-1), and interleukin-6 (IL-6).
2. Host response: The body's response to the presence of cancer can also contribute to cachexia. This response includes the production of certain substances by the immune system, which, like the tumour-induced factors, can lead to muscle and fat tissue wasting.
3. Nutritional impact: The presence of a tumour can impact a patient's nutritional status, either directly through the mechanical effects of the tumour (for example, a tumour in the gastrointestinal tract may interfere with food intake or nutrient absorption), or indirectly through symptoms such as loss of appetite or changes in taste and smell.
4. Metabolic changes: There are also changes in the way the body uses and stores nutrients, such as proteins, fats, and carbohydrates. These changes, which can be caused by both the tumour and the body's response to it, can lead to weight loss and muscle wasting.

Given the complex nature of cancer cachexia, it is often difficult to treat effectively, and comprehensive, multidisciplinary strategies that address all aspects of the condition are usually required. This can include nutritional support, physical therapy, and medications to stimulate appetite or inhibit muscle breakdown.

Cancer Cachexia Epidemiology
Cancer cachexia can be analysed based on several factors such as prevalence, age, gender, and lifestyle habits.
  • Prevalence: Cancer cachexia is most common in patients with certain types of cancer, such as pancreatic, gastric, oesophageal, colon, and head and neck cancers. Studies suggest that approximately 50-80% of all cancer patients experience cachexia, with the highest incidence found in advanced-stage cancer patients. This high prevalence of cancer cachexia drives the demand for effective treatments, thereby influencing the market dynamics
  • Age: Cancer cachexia tends to affect older adults more frequently, primarily because cancer itself is more common in older populations. As the global population continues to age, it is anticipated that the incidence of cancer and associated conditions like cachexia will increase, contributing to the market growth
  • Gender: While both males and females are affected by cancer cachexia, some studies suggest a slightly higher prevalence in males. However, gender-based differences in the incidence of cachexia may vary depending on the type of cancer and other factors, which necessitates further research
  • Lifestyle Habits: Smoking, excessive alcohol consumption, poor nutrition, and physical inactivity are all lifestyle habits that can increase the risk of cancer and consequently cancer cachexia. Populations with these lifestyle habits may see a higher prevalence of cachexia, influencing the demand for related treatments
In the division of the market based on these factors, it becomes clear that segments with higher cancer prevalence, older age demographics, certain lifestyle habits, and potentially male gender, may represent key target markets for manufacturers of drugs and therapies for cancer cachexia. However, it is crucial to note that the treatment of cancer cachexia requires a multidisciplinary approach, due to the multifactorial nature of the syndrome. This includes nutritional support and physical therapy, in addition to pharmacological interventions

Cancer Cachexia Market Segmentations

The market can be categorised into therapeutics, mechanism of action, distribution channel, and region.

Market Breakup by Therapeutics

  • Progestogens
  • Corticosteroids
  • Combination Therapies
  • Cannabinoids
  • Nonsteroidal anti-inflammatory drugs
  • Anabolic agents
  • Immunomodulatory agents
  • Ghrelin receptor agonists
  • Others

Market Breakup by Mechanism of action

  • Appetite Stimulators
  • Weight Loss Stabilizers

Market Breakup by Distribution channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Cancer Cachexia Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cancer Cachexia Market Scenario

The global cancer cachexia market is undergoing significant evolution. This is largely due to the increasing prevalence of cancer across the world, which in turn triggers a higher incidence of cachexia, a debilitating condition often associated with advanced stages of the disease. As of 2023, the market continues to see an upward trend in demand for effective therapeutics, driven by rising patient awareness, the development of innovative treatments, and an increase in research funding.

Key Trends
In terms of geography, North America holds the largest market share, followed by Europe. This is attributed to the advanced healthcare infrastructure, the presence of leading pharmaceutical companies, and higher cancer prevalence in these regions. However, Asia-Pacific is expected to witness the fastest growth due to an increasing patient pool, improving healthcare facilities, and growing awareness about cancer cachexia.

The market is characterized by a robust pipeline of drugs, with several promising candidates in various stages of clinical trials. The pharmaceutical industry has been investing heavily in research and development activities to discover effective therapies for cancer cachexia. The market's growth potential has attracted several biopharmaceutical companies and research institutes, which are now focusing on developing novel drugs and therapies.

Despite these advancements, the market faces certain challenges that could slow its growth. One of the significant challenges is the lack of a standardized diagnostic criteria for cancer cachexia, which often leads to late-stage diagnosis. This, coupled with a low level of awareness about the condition, hampers the timely treatment of patients.

Another major challenge is the complexity of the disease itself. Cancer cachexia is a multifactorial syndrome, making its management quite complex. This complexity is reflected in the drug development process, where potential therapies need to address a variety of symptoms and underlying mechanisms. Thus, the high failure rate of clinical trials is a major hurdle in the development of effective treatments.

Furthermore, the market is somewhat restrained by the high cost of therapy and limited accessibility in certain regions. Particularly in developing countries, these factors can limit the number of patients who are able to receive treatment.

In conclusion, while the global cancer cachexia market faces some substantial challenges, it also presents considerable opportunities. Continued research and development efforts, coupled with increased awareness and improved diagnostic methods, will be key to unlocking its full potential.

Key Players in the Global Cancer Cachexia Market

The report gives an in-depth analysis of the key players involved in the cancer cachexia market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Aeterna Zentaris Inc
  • Aphios Corporation
  • Atara Biotherapeutics Inc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GTx, Inc
  • Helsinn Group
  • Merck & Co., Inc
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd
  • Pfizer Inc
  • XBiotech Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Cachexia Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Cachexia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Cachexia Epidemiology (2016-2031)
5.3 Europe Cancer Cachexia Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Cachexia Epidemiology (2016-2031)
5.5 Latin America Cancer Cachexia Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Cachexia Epidemiology (2016-2031)
6 Global Cancer Cachexia Market Overview
6.1 Global Cancer Cachexia Market Historical Value (2016-2022)
6.2 Global Cancer Cachexia Market Forecast Value (2023-2031)
7 Global Cancer Cachexia Market Landscape
7.1 Global Cancer Cachexia Market: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cancer Cachexia Market: Product Landscape
7.2.1 Analysis by Therapeutics
7.2.2 Analysis by Mode of Action
7.2.3 Analysis by Distribution Channel
8 Cancer Cachexia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cancer Cachexia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cancer Cachexia Market Segmentation
11.1 Global Cancer Cachexia Market by Therapeutics
11.1.1 Market Overview
11.1.2 Progestogens
11.1.3 Corticosteroids
11.1.4 Combination Therapies
11.1.5 Cannabinoids
11.1.6 Nonsteroidal anti-inflammatory drugs
11.1.7 Anabolic agents
11.1.8 Immunomodulatory agents
11.1.9 Ghrelin receptor agonists
11.1.10 Others
11.2 Global Cancer Cachexia Market by Mechanism of Action
11.2.1 Market Overview
11.2.2 Appetite Stimulators
11.2.3 Weight Loss Stabilizers
11.3 Global Cancer Cachexia Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacy
11.3.5 Others
11.4 Global Cancer Cachexia Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Cancer Cachexia Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cancer Cachexia Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cancer Cachexia Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cancer Cachexia Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cancer Cachexia Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Aeterna Zentaris Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Aphios Corporation
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Atara Biotherapeutics Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Bristol-Myers Squibb Company
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Eli Lilly and Company
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GTx, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Helsinn Group
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Merck & Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Novartis AG
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ono Pharmaceutical Co., Ltd.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Pfizer Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 XBiotech Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Cancer Cachexia Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Atara Biotherapeutics Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gtx, Inc.
  • Helsinn Group
  • Merck & Co. Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Xbiotech Inc.



Table Information